AzTrials
AzTrials

LaryngoscopyNCT00926718

The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy

A study testing remifentanil infusion and rocuronium dose + remifentanil infusion in people with Laryngoscopy, run by St. Vincent's Medical Center at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Eighty subjects will be recruited from those scheduled for surgery requiring general anesthesia at St Vincent's Hospital. Subjects must have American Society of Anesthesiologists (ASA) status of 1 or 2 (be fairly healthy), a BMI between 18-35 (reasonably healthy weight), and be between the ages of 18 and 75. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Laryngoscopy
What is being tested?
remifentanil infusion and rocuronium dose + remifentanil infusion
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteUnited States
Study dates
Jun 2009to Jun 2010
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Presence of ASA physical status class I or II. (This will exclude subjects with significant medical problems).
  • Body mass index between 18 and 35 kg m-2.
  • No use of psychotropic or neuropsychiatric medications.
  • A airway assessment with no indication of a difficult intubation including a class I or II Malampatti airway and a mandible-to-hyoid distance of greater than three fingerbreadths.
  • Age between 18-75 years.

Who cannot join

  • Does not meet inclusion criteria.

Trial locations and contacts

1 site in 1 country.

Donald Mathews, MD contact

212-604-7566

dmathews@svcmcny.org

United States1 site, 1 recruiting
  • Saint Vincent Catholic Medical Centers

    New York, New York, 10011

    Donald Mathews, MD, 212-604-7566, dmathews@svcmcny.org

    Donald Mathews, MD

    Recruiting

Other trials in United States

About this study

Official title: The Effect of Rocuronium on the Response of CVI to Laryngoscopy

Eighty subjects will be recruited from those scheduled for surgery requiring general anesthesia at St Vincent's Hospital. Subjects must have American Society of Anesthesiologists (ASA) status of 1 or 2 (be fairly healthy), a BMI between 18-35 (reasonably healthy weight), and be between the ages of 18 and 75. They will not be eligible if they take certain medications or are expected to have a difficult intubation.

Subjects will be randomized (assigned by chance) to one of four rocuronium doses of 0, 0.2, 0.4, or 0.6 mg kg-1. All are acceptable clinical doses for performing a laryngoscopy. In the operating room, routine monitors will be applied, including a Bispectral Index (BIS) sensor and an M-Entropy sensor. Subjects will receive 0.025 mg kg-1 midazolam (a standard pre-op dose) and will be put to sleep. Once asleep, the subject will receive a rocuronium dose, followed by laryngoscopy three minutes later. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. CVI, entropy, amount of muscle relaxation, and vital signs will be monitored and recorded throughout the procedure.

Read more

Subjects will receive propofol and remifentanil infusions during the case. These are commonly used medications for anesthesia. The subjects will also be randomized to two additional groups. One group will receive a remifentanil infusion of 2ng ml-1 and the other group will receive a 8ng ml-1 remifentanil infusion. Both doses are acceptable and often used during standard clinical care. The propofol infusion will be adjusted to keep the BIS number between 45-60. The anesthesiologist will not be able to see the CVI value. The times of certain intraoperative events, such as intubation and incision, will be recorded. All subjects will receive a morphine bolus (0.10-0.15 mg/kg) towards the end to reduce post-operative pain, as per standard clinical care. As the subject wakes up, time to eye opening and orientation will be recorded. The subject will rate their pain on a numerical pain scale and the quality of emergence will be assessed.

Upon arrival in the post anesthesia care unit (PACU), subjects will be asked to rate their pain again using the same pain scale. The pain score will be evaluated every 10 minutes for half an hour, then every hour until they are discharged from PACU.

Read the detailed description

The Composite Variability Index (CVI, Aspect Medical System, Norwood MA) is a new parameter (measurement) that provides information about the amount of painful stimulation during surgery. It is part of the Bispectral Index (BIS, Aspect Medical Systems, Norwood MA), a well-established and widely used parameter that shows how awake/asleep patients are during general anesthesia and may indicate a need for more medication. The CVI component provides specific information about whether the patient needs pain medication (called opioids) and not just medication that makes you sleep (called hypnotics). The CVI is made of the BIS number and a measure of facial muscle movement (EMG). Both these components increase with painful stimulation, and decrease when pain medication is given.

Neuromuscular blocking drugs (NMD) are paralyzing medications that are often used during surgery to relax the body and make it easier for the surgeon to perform the surgery and the anesthesiologist to insert the breathing tube (called intubation). Facial muscles are resistant to NMD effects, but they might affect the EMG reading, making the CVI less useful when a patient needs NMD. The M-entropy monitor (GE Healthcare, Helsinki, Finland) is similar to the BIS monitor with CVI and is affected by large NMD doses. The purpose of this study is to examine the effect of rocuronium, a NMD, on the response of CVI and M-entropy to laryngoscopy under anesthesia. A laryngoscopy is the standard way of examining and opening the patient's airway before inserting the breathing tube. It is fairly stimulating so anesthesiologists sometimes, but not always, administer a NMD (in varying doses) before performing the laryngoscopy in standard care.

Eighty subjects will be recruited from those scheduled for surgery requiring general anesthesia at St Vincent's Hospital. Subjects must have ASA status of 1 or 2 (be fairly healthy), a BMI between 18-35 (reasonably healthy weight), and be between the ages of 18 and 75. They will not be eligible if they take certain medications or are expected to have a difficult intubation.

Subjects will be randomized (assigned by chance) to one of four rocuronium doses of 0, 0.2, 0.4, or 0.6 mg kg-1. All are acceptable clinical doses for performing a laryngoscopy. In the operating room, routine monitors will be applied, including a BIS sensor and an M-Entropy sensor. Subjects will receive 0.025 mg kg-1 midazolam (a standard pre-op dose) and will be put to sleep. Once asleep, the subject will receive a rocuronium dose, followed by laryngoscopy three minutes later. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. CVI, entropy, amount of muscle relaxation, and vital signs will be monitored and recorded throughout the procedure.

Subjects will receive propofol and remifentanil infusions during the case. These are commonly used medications for anesthesia. The subjects will also be randomized (assigned by chance) to two additional groups. One group will receive a remifentanil infusion of 2ng ml-1 and the other group will receive a 8ng ml-1 remifentanil infusion. Both doses are acceptable and often used during standard clinical care. The propofol infusion will be adjusted to keep the BIS number between 45-60. The anesthesiologist will not be able to see the CVI value. The times of certain intraoperative events, such as intubation and incision, will be recorded. All subjects will receive a morphine bolus (0.10-0.15 mg/kg) towards the end to reduce post-operative pain, as per standard clinical care. As the subject wakes up, time to eye opening and orientation will be recorded. The subject will rate their pain on a numerical pain scale and the quality of emergence will be assessed.

Upon arrival in the PACU, subjects will be asked to rate their pain again using the same pain scale. The pain score will be evaluated every 10 minutes for half an hour, then every hour until they are discharged from PACU. The total dose of pain medications administered in PACU will be recorded. Upon PACU discharge, subjects will be asked to rate their overall experience with anesthesia. Demographic data will also be collected. All data will be kept in locked file cabinets and study results will be shared with research personnel at Aspect Medical Systems.

Conditions
Laryngoscopy
Being tested
remifentanil infusion, rocuronium dose + remifentanil infusion
Keywords
BIS monitor, rocuronium, The effect of the neuromuscular blocking drug rocuronium on the response of the Composite Variability Index to laryngoscopy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • remifentanil infusionDrug

    rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1

  • rocuronium dose + remifentanil infusionDrug

    rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1

  • rocuronium dose + remifentanil infusionDrug

    rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1

  • remifentanil infusionDrug

    rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1

  • rocuronium dose + remifentanil infusionDrug

    rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1

  • rocuronium dose + remifentanil infusionDrug

    rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1

Study groups in NCT00926718
Study groupRoleWhat they receive
Dose 1aExperimentalNot described
Receives: Drug: remifentanil infusion
Dose 2aExperimentalNot described
Receives: Drug: rocuronium dose + remifentanil infusion
Dose 3aExperimentalNot described
Receives: Drug: rocuronium dose + remifentanil infusion
Dose 1bExperimentalNot described
Receives: Drug: remifentanil infusion
Dose 2bExperimentalNot described
Receives: Drug: rocuronium dose + remifentanil infusion
Dose 3bExperimentalNot described
Receives: Drug: rocuronium dose + remifentanil infusion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Variable response to medication given.

    Measured: 1-6 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jun 2009 (estimated)
  2. Study startJun 2009
  3. Primary completionJun 2010 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00926718
Sponsor's protocol ID
SVCMC_09_021
Status last verified
Jun 2009
First submitted
19 Jun 2009
Last updated
23 Jun 2009
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing remifentanil infusion and rocuronium dose + remifentanil infusion in people with Laryngoscopy, run by St. Vincent's Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jun 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Donald Mathews, MD (212-604-7566, dmathews@svcmcny.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Variable response to medication given. (time frame: 1-6 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in